Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
Persistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide. To evaluate the harms and protection of prophylactic human papillomaviruses (H...
Saved in:
| Published in: | Cochrane database of systematic reviews Vol. 5; p. CD009069 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
09.05.2018
|
| Subjects: | |
| ISSN: | 1469-493X, 1469-493X |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Persistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide.
To evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women.
We searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase (June 2017) for reports on effects from trials. We searched trial registries and company results' registers to identify unpublished data for mortality and serious adverse events.
Randomised controlled trials comparing efficacy and safety in females offered HPV vaccines with placebo (vaccine adjuvants or another control vaccine).
We used Cochrane methodology and GRADE to rate the certainty of evidence for protection against cervical precancer (cervical intraepithelial neoplasia grade 2 and above [CIN2+], CIN grade 3 and above [CIN3+], and adenocarcinoma-in-situ [AIS]), and for harms. We distinguished between the effects of vaccines by participants' baseline HPV DNA status. The outcomes were precancer associated with vaccine HPV types and precancer irrespective of HPV type. Results are presented as risks in control and vaccination groups and risk ratios (RR) with 95% confidence intervals in brackets.
We included 26 trials (73,428 participants). Ten trials, with follow-up of 1.3 to 8 years, addressed protection against CIN/AIS. Vaccine safety was evaluated over a period of 6 months to 7 years in 23 studies. Studies were not large enough or of sufficient duration to evaluate cervical cancer outcomes. All but one of the trials was funded by the vaccine manufacturers. We judged most included trials to be at low risk of bias. Studies involved monovalent (N = 1), bivalent (N = 18), and quadrivalent vaccines (N = 7). Most women were under 26 years of age. Three trials recruited women aged 25 and over. We summarize the effects of vaccines in participants who had at least one immunisation.Efficacy endpoints by initial HPV DNA statushrHPV negativeHPV vaccines reduce CIN2+, CIN3+, AIS associated with HPV16/18 compared with placebo in adolescent girls and women aged 15 to 26. There is high-certainty evidence that vaccines lower CIN2+ from 164 to 2/10,000 (RR 0.01 (0 to 0.05)) and CIN3+ from 70 to 0/10,000 (RR 0.01 (0.00 to 0.10). There is moderate-certainty evidence that vaccines reduce the risk of AIS from 9 to 0/10,000 (RR 0.10 (0.01 to 0.82).HPV vaccines reduce the risk of any CIN2+ from 287 to 106/10,000 (RR 0.37 (0.25 to 0.55), high certainty) and probably reduce any AIS lesions from 10 to 0/10,000 (RR 0.1 (0.01 to 0.76), moderate certainty). The size of reduction in CIN3+ with vaccines differed between bivalent and quadrivalent vaccines (bivalent: RR 0.08 (0.03 to 0.23), high certainty; quadrivalent: RR 0.54 (0.36 to 0.82), moderate certainty). Data in older women were not available for this comparison.HPV16/18 negativeIn those aged 15 to 26 years, vaccines reduce CIN2+ associated with HPV16/18 from 113 to 6 /10,000 (RR 0.05 (0.03 to 0.10). In women 24 years or older the absolute and relative reduction in the risk of these lesions is smaller (from 45 to 14/10,000, (RR 0.30 (0.11 to 0.81), moderate certainty). HPV vaccines reduce the risk of CIN3+ and AIS associated with HPV16/18 in younger women (RR 0.05 (0.02 to 0.14), high certainty and RR 0.09 (0.01 to 0.72), moderate certainty, respectively). No trials in older women have measured these outcomes.Vaccines reduce any CIN2+ from 231 to 95/10,000, (RR 0.41 (0.32 to 0.52)) in younger women. No data are reported for more severe lesions.Regardless of HPV DNA statusIn younger women HPV vaccines reduce the risk of CIN2+ associated with HPV16/18 from 341 to 157/10,000 (RR 0.46 (0.37 to 0.57), high certainty). Similar reductions in risk were observed for CIN3+ associated with HPV16/18 (high certainty). The number of women with AIS associated with HPV16/18 is reduced from 14 to 5/10,000 with HPV vaccines (high certainty).HPV vaccines reduce any CIN2+ from 559 to 391/10,000 (RR 0.70 (0.58 to 0.85, high certainty) and any AIS from 17 to 5/10,000 (RR 0.32 (0.15 to 0.67), high certainty). The reduction in any CIN3+ differed by vaccine type (bivalent vaccine: RR 0.55 (0.43 to 0.71) and quadrivalent vaccine: RR 0.81 (0.69 to 0.96)).In women vaccinated at 24 to 45 years of age, there is moderate-certainty evidence that the risks of CIN2+ associated with HPV16/18 and any CIN2+ are similar between vaccinated and unvaccinated women (RR 0.74 (0.52 to 1.05) and RR 1.04 (0.83 to 1.30) respectively). No data are reported in this age group for CIN3+ or AIS.Adverse effectsThe risk of serious adverse events is similar between control and HPV vaccines in women of all ages (669 versus 656/10,000, RR 0.98 (0.92 to 1.05), high certainty). Mortality was 11/10,000 in control groups compared with 14/10,000 (9 to 22) with HPV vaccine (RR 1.29 [0.85 to 1.98]; low certainty). The number of deaths was low overall but there is a higher number of deaths in older women. No pattern in the cause or timing of death has been established.Pregnancy outcomesAmong those who became pregnant during the studies, we did not find an increased risk of miscarriage (1618 versus 1424/10,000, RR 0.88 (0.68 to 1.14), high certainty) or termination (931 versus 838/10,000 RR 0.90 (0.80 to 1.02), high certainty). The effects on congenital abnormalities and stillbirths are uncertain (RR 1.22 (0.88 to 1.69), moderate certainty and (RR 1.12 (0.68 to 1.83), moderate certainty, respectively).
There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26. The effect is higher for lesions associated with HPV16/18 than for lesions irrespective of HPV type. The effect is greater in those who are negative for hrHPV or HPV16/18 DNA at enrolment than those unselected for HPV DNA status. There is moderate-certainty evidence that HPV vaccines reduce CIN2+ in older women who are HPV16/18 negative, but not when they are unselected by HPV DNA status.We did not find an increased risk of serious adverse effects. Although the number of deaths is low overall, there were more deaths among women older than 25 years who received the vaccine. The deaths reported in the studies have been judged not to be related to the vaccine. Increased risk of adverse pregnancy outcomes after HPV vaccination cannot be excluded, although the risk of miscarriage and termination are similar between trial arms. Long-term of follow-up is needed to monitor the impact on cervical cancer, occurrence of rare harms and pregnancy outcomes. |
|---|---|
| AbstractList | Persistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide.
To evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women.
We searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase (June 2017) for reports on effects from trials. We searched trial registries and company results' registers to identify unpublished data for mortality and serious adverse events.
Randomised controlled trials comparing efficacy and safety in females offered HPV vaccines with placebo (vaccine adjuvants or another control vaccine).
We used Cochrane methodology and GRADE to rate the certainty of evidence for protection against cervical precancer (cervical intraepithelial neoplasia grade 2 and above [CIN2+], CIN grade 3 and above [CIN3+], and adenocarcinoma-in-situ [AIS]), and for harms. We distinguished between the effects of vaccines by participants' baseline HPV DNA status. The outcomes were precancer associated with vaccine HPV types and precancer irrespective of HPV type. Results are presented as risks in control and vaccination groups and risk ratios (RR) with 95% confidence intervals in brackets.
We included 26 trials (73,428 participants). Ten trials, with follow-up of 1.3 to 8 years, addressed protection against CIN/AIS. Vaccine safety was evaluated over a period of 6 months to 7 years in 23 studies. Studies were not large enough or of sufficient duration to evaluate cervical cancer outcomes. All but one of the trials was funded by the vaccine manufacturers. We judged most included trials to be at low risk of bias. Studies involved monovalent (N = 1), bivalent (N = 18), and quadrivalent vaccines (N = 7). Most women were under 26 years of age. Three trials recruited women aged 25 and over. We summarize the effects of vaccines in participants who had at least one immunisation.Efficacy endpoints by initial HPV DNA statushrHPV negativeHPV vaccines reduce CIN2+, CIN3+, AIS associated with HPV16/18 compared with placebo in adolescent girls and women aged 15 to 26. There is high-certainty evidence that vaccines lower CIN2+ from 164 to 2/10,000 (RR 0.01 (0 to 0.05)) and CIN3+ from 70 to 0/10,000 (RR 0.01 (0.00 to 0.10). There is moderate-certainty evidence that vaccines reduce the risk of AIS from 9 to 0/10,000 (RR 0.10 (0.01 to 0.82).HPV vaccines reduce the risk of any CIN2+ from 287 to 106/10,000 (RR 0.37 (0.25 to 0.55), high certainty) and probably reduce any AIS lesions from 10 to 0/10,000 (RR 0.1 (0.01 to 0.76), moderate certainty). The size of reduction in CIN3+ with vaccines differed between bivalent and quadrivalent vaccines (bivalent: RR 0.08 (0.03 to 0.23), high certainty; quadrivalent: RR 0.54 (0.36 to 0.82), moderate certainty). Data in older women were not available for this comparison.HPV16/18 negativeIn those aged 15 to 26 years, vaccines reduce CIN2+ associated with HPV16/18 from 113 to 6 /10,000 (RR 0.05 (0.03 to 0.10). In women 24 years or older the absolute and relative reduction in the risk of these lesions is smaller (from 45 to 14/10,000, (RR 0.30 (0.11 to 0.81), moderate certainty). HPV vaccines reduce the risk of CIN3+ and AIS associated with HPV16/18 in younger women (RR 0.05 (0.02 to 0.14), high certainty and RR 0.09 (0.01 to 0.72), moderate certainty, respectively). No trials in older women have measured these outcomes.Vaccines reduce any CIN2+ from 231 to 95/10,000, (RR 0.41 (0.32 to 0.52)) in younger women. No data are reported for more severe lesions.Regardless of HPV DNA statusIn younger women HPV vaccines reduce the risk of CIN2+ associated with HPV16/18 from 341 to 157/10,000 (RR 0.46 (0.37 to 0.57), high certainty). Similar reductions in risk were observed for CIN3+ associated with HPV16/18 (high certainty). The number of women with AIS associated with HPV16/18 is reduced from 14 to 5/10,000 with HPV vaccines (high certainty).HPV vaccines reduce any CIN2+ from 559 to 391/10,000 (RR 0.70 (0.58 to 0.85, high certainty) and any AIS from 17 to 5/10,000 (RR 0.32 (0.15 to 0.67), high certainty). The reduction in any CIN3+ differed by vaccine type (bivalent vaccine: RR 0.55 (0.43 to 0.71) and quadrivalent vaccine: RR 0.81 (0.69 to 0.96)).In women vaccinated at 24 to 45 years of age, there is moderate-certainty evidence that the risks of CIN2+ associated with HPV16/18 and any CIN2+ are similar between vaccinated and unvaccinated women (RR 0.74 (0.52 to 1.05) and RR 1.04 (0.83 to 1.30) respectively). No data are reported in this age group for CIN3+ or AIS.Adverse effectsThe risk of serious adverse events is similar between control and HPV vaccines in women of all ages (669 versus 656/10,000, RR 0.98 (0.92 to 1.05), high certainty). Mortality was 11/10,000 in control groups compared with 14/10,000 (9 to 22) with HPV vaccine (RR 1.29 [0.85 to 1.98]; low certainty). The number of deaths was low overall but there is a higher number of deaths in older women. No pattern in the cause or timing of death has been established.Pregnancy outcomesAmong those who became pregnant during the studies, we did not find an increased risk of miscarriage (1618 versus 1424/10,000, RR 0.88 (0.68 to 1.14), high certainty) or termination (931 versus 838/10,000 RR 0.90 (0.80 to 1.02), high certainty). The effects on congenital abnormalities and stillbirths are uncertain (RR 1.22 (0.88 to 1.69), moderate certainty and (RR 1.12 (0.68 to 1.83), moderate certainty, respectively).
There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26. The effect is higher for lesions associated with HPV16/18 than for lesions irrespective of HPV type. The effect is greater in those who are negative for hrHPV or HPV16/18 DNA at enrolment than those unselected for HPV DNA status. There is moderate-certainty evidence that HPV vaccines reduce CIN2+ in older women who are HPV16/18 negative, but not when they are unselected by HPV DNA status.We did not find an increased risk of serious adverse effects. Although the number of deaths is low overall, there were more deaths among women older than 25 years who received the vaccine. The deaths reported in the studies have been judged not to be related to the vaccine. Increased risk of adverse pregnancy outcomes after HPV vaccination cannot be excluded, although the risk of miscarriage and termination are similar between trial arms. Long-term of follow-up is needed to monitor the impact on cervical cancer, occurrence of rare harms and pregnancy outcomes. Persistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide.BACKGROUNDPersistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide.To evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women.OBJECTIVESTo evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women.We searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase (June 2017) for reports on effects from trials. We searched trial registries and company results' registers to identify unpublished data for mortality and serious adverse events.SEARCH METHODSWe searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase (June 2017) for reports on effects from trials. We searched trial registries and company results' registers to identify unpublished data for mortality and serious adverse events.Randomised controlled trials comparing efficacy and safety in females offered HPV vaccines with placebo (vaccine adjuvants or another control vaccine).SELECTION CRITERIARandomised controlled trials comparing efficacy and safety in females offered HPV vaccines with placebo (vaccine adjuvants or another control vaccine).We used Cochrane methodology and GRADE to rate the certainty of evidence for protection against cervical precancer (cervical intraepithelial neoplasia grade 2 and above [CIN2+], CIN grade 3 and above [CIN3+], and adenocarcinoma-in-situ [AIS]), and for harms. We distinguished between the effects of vaccines by participants' baseline HPV DNA status. The outcomes were precancer associated with vaccine HPV types and precancer irrespective of HPV type. Results are presented as risks in control and vaccination groups and risk ratios (RR) with 95% confidence intervals in brackets.DATA COLLECTION AND ANALYSISWe used Cochrane methodology and GRADE to rate the certainty of evidence for protection against cervical precancer (cervical intraepithelial neoplasia grade 2 and above [CIN2+], CIN grade 3 and above [CIN3+], and adenocarcinoma-in-situ [AIS]), and for harms. We distinguished between the effects of vaccines by participants' baseline HPV DNA status. The outcomes were precancer associated with vaccine HPV types and precancer irrespective of HPV type. Results are presented as risks in control and vaccination groups and risk ratios (RR) with 95% confidence intervals in brackets.We included 26 trials (73,428 participants). Ten trials, with follow-up of 1.3 to 8 years, addressed protection against CIN/AIS. Vaccine safety was evaluated over a period of 6 months to 7 years in 23 studies. Studies were not large enough or of sufficient duration to evaluate cervical cancer outcomes. All but one of the trials was funded by the vaccine manufacturers. We judged most included trials to be at low risk of bias. Studies involved monovalent (N = 1), bivalent (N = 18), and quadrivalent vaccines (N = 7). Most women were under 26 years of age. Three trials recruited women aged 25 and over. We summarize the effects of vaccines in participants who had at least one immunisation.Efficacy endpoints by initial HPV DNA statushrHPV negativeHPV vaccines reduce CIN2+, CIN3+, AIS associated with HPV16/18 compared with placebo in adolescent girls and women aged 15 to 26. There is high-certainty evidence that vaccines lower CIN2+ from 164 to 2/10,000 (RR 0.01 (0 to 0.05)) and CIN3+ from 70 to 0/10,000 (RR 0.01 (0.00 to 0.10). There is moderate-certainty evidence that vaccines reduce the risk of AIS from 9 to 0/10,000 (RR 0.10 (0.01 to 0.82).HPV vaccines reduce the risk of any CIN2+ from 287 to 106/10,000 (RR 0.37 (0.25 to 0.55), high certainty) and probably reduce any AIS lesions from 10 to 0/10,000 (RR 0.1 (0.01 to 0.76), moderate certainty). The size of reduction in CIN3+ with vaccines differed between bivalent and quadrivalent vaccines (bivalent: RR 0.08 (0.03 to 0.23), high certainty; quadrivalent: RR 0.54 (0.36 to 0.82), moderate certainty). Data in older women were not available for this comparison.HPV16/18 negativeIn those aged 15 to 26 years, vaccines reduce CIN2+ associated with HPV16/18 from 113 to 6 /10,000 (RR 0.05 (0.03 to 0.10). In women 24 years or older the absolute and relative reduction in the risk of these lesions is smaller (from 45 to 14/10,000, (RR 0.30 (0.11 to 0.81), moderate certainty). HPV vaccines reduce the risk of CIN3+ and AIS associated with HPV16/18 in younger women (RR 0.05 (0.02 to 0.14), high certainty and RR 0.09 (0.01 to 0.72), moderate certainty, respectively). No trials in older women have measured these outcomes.Vaccines reduce any CIN2+ from 231 to 95/10,000, (RR 0.41 (0.32 to 0.52)) in younger women. No data are reported for more severe lesions.Regardless of HPV DNA statusIn younger women HPV vaccines reduce the risk of CIN2+ associated with HPV16/18 from 341 to 157/10,000 (RR 0.46 (0.37 to 0.57), high certainty). Similar reductions in risk were observed for CIN3+ associated with HPV16/18 (high certainty). The number of women with AIS associated with HPV16/18 is reduced from 14 to 5/10,000 with HPV vaccines (high certainty).HPV vaccines reduce any CIN2+ from 559 to 391/10,000 (RR 0.70 (0.58 to 0.85, high certainty) and any AIS from 17 to 5/10,000 (RR 0.32 (0.15 to 0.67), high certainty). The reduction in any CIN3+ differed by vaccine type (bivalent vaccine: RR 0.55 (0.43 to 0.71) and quadrivalent vaccine: RR 0.81 (0.69 to 0.96)).In women vaccinated at 24 to 45 years of age, there is moderate-certainty evidence that the risks of CIN2+ associated with HPV16/18 and any CIN2+ are similar between vaccinated and unvaccinated women (RR 0.74 (0.52 to 1.05) and RR 1.04 (0.83 to 1.30) respectively). No data are reported in this age group for CIN3+ or AIS.Adverse effectsThe risk of serious adverse events is similar between control and HPV vaccines in women of all ages (669 versus 656/10,000, RR 0.98 (0.92 to 1.05), high certainty). Mortality was 11/10,000 in control groups compared with 14/10,000 (9 to 22) with HPV vaccine (RR 1.29 [0.85 to 1.98]; low certainty). The number of deaths was low overall but there is a higher number of deaths in older women. No pattern in the cause or timing of death has been established.Pregnancy outcomesAmong those who became pregnant during the studies, we did not find an increased risk of miscarriage (1618 versus 1424/10,000, RR 0.88 (0.68 to 1.14), high certainty) or termination (931 versus 838/10,000 RR 0.90 (0.80 to 1.02), high certainty). The effects on congenital abnormalities and stillbirths are uncertain (RR 1.22 (0.88 to 1.69), moderate certainty and (RR 1.12 (0.68 to 1.83), moderate certainty, respectively).MAIN RESULTSWe included 26 trials (73,428 participants). Ten trials, with follow-up of 1.3 to 8 years, addressed protection against CIN/AIS. Vaccine safety was evaluated over a period of 6 months to 7 years in 23 studies. Studies were not large enough or of sufficient duration to evaluate cervical cancer outcomes. All but one of the trials was funded by the vaccine manufacturers. We judged most included trials to be at low risk of bias. Studies involved monovalent (N = 1), bivalent (N = 18), and quadrivalent vaccines (N = 7). Most women were under 26 years of age. Three trials recruited women aged 25 and over. We summarize the effects of vaccines in participants who had at least one immunisation.Efficacy endpoints by initial HPV DNA statushrHPV negativeHPV vaccines reduce CIN2+, CIN3+, AIS associated with HPV16/18 compared with placebo in adolescent girls and women aged 15 to 26. There is high-certainty evidence that vaccines lower CIN2+ from 164 to 2/10,000 (RR 0.01 (0 to 0.05)) and CIN3+ from 70 to 0/10,000 (RR 0.01 (0.00 to 0.10). There is moderate-certainty evidence that vaccines reduce the risk of AIS from 9 to 0/10,000 (RR 0.10 (0.01 to 0.82).HPV vaccines reduce the risk of any CIN2+ from 287 to 106/10,000 (RR 0.37 (0.25 to 0.55), high certainty) and probably reduce any AIS lesions from 10 to 0/10,000 (RR 0.1 (0.01 to 0.76), moderate certainty). The size of reduction in CIN3+ with vaccines differed between bivalent and quadrivalent vaccines (bivalent: RR 0.08 (0.03 to 0.23), high certainty; quadrivalent: RR 0.54 (0.36 to 0.82), moderate certainty). Data in older women were not available for this comparison.HPV16/18 negativeIn those aged 15 to 26 years, vaccines reduce CIN2+ associated with HPV16/18 from 113 to 6 /10,000 (RR 0.05 (0.03 to 0.10). In women 24 years or older the absolute and relative reduction in the risk of these lesions is smaller (from 45 to 14/10,000, (RR 0.30 (0.11 to 0.81), moderate certainty). HPV vaccines reduce the risk of CIN3+ and AIS associated with HPV16/18 in younger women (RR 0.05 (0.02 to 0.14), high certainty and RR 0.09 (0.01 to 0.72), moderate certainty, respectively). No trials in older women have measured these outcomes.Vaccines reduce any CIN2+ from 231 to 95/10,000, (RR 0.41 (0.32 to 0.52)) in younger women. No data are reported for more severe lesions.Regardless of HPV DNA statusIn younger women HPV vaccines reduce the risk of CIN2+ associated with HPV16/18 from 341 to 157/10,000 (RR 0.46 (0.37 to 0.57), high certainty). Similar reductions in risk were observed for CIN3+ associated with HPV16/18 (high certainty). The number of women with AIS associated with HPV16/18 is reduced from 14 to 5/10,000 with HPV vaccines (high certainty).HPV vaccines reduce any CIN2+ from 559 to 391/10,000 (RR 0.70 (0.58 to 0.85, high certainty) and any AIS from 17 to 5/10,000 (RR 0.32 (0.15 to 0.67), high certainty |
| Author | Simoens, Cindy Martin-Hirsch, Pierre Pl Arbyn, Marc Xu, Lan |
| Author_xml | – sequence: 1 givenname: Marc surname: Arbyn fullname: Arbyn, Marc organization: Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Juliette Wytsmanstreet 14, Brussels, Belgium, B-1050 – sequence: 2 givenname: Lan surname: Xu fullname: Xu, Lan – sequence: 3 givenname: Cindy surname: Simoens fullname: Simoens, Cindy – sequence: 4 givenname: Pierre Pl surname: Martin-Hirsch fullname: Martin-Hirsch, Pierre Pl |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29740819$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLxDAUhYMozkP_wpClm455tGmylPEJA7pQcFdu01sn0qY1aQvz7x1xBFfng_NxFmdBTn3nkZAVZ2vOmLjmqcq4zvR6c8uYYcqs-7GUJ2R-KEySGvl--o9nZBHjJ2PScK7PyUyYPGWamznBl9D1u30DdnCWTmCt8zC4zlP4AOfjQHdjC5720Lum6VqYXBgjRjp0tA84oR-oxTA5Cw214A9MwVfUDfGnt2OIXYgX5KyGJuLlMZfk7f7udfOYbJ8fnjY328Rm0sgk1apCoRnLTGmgNJVUrDZ5LqUEJWpthTVpqljFMwsIaEqBXEkGkGGNUoslufrd7UP3NWIcitZFi00DHrsxFoJJlWvDZHZQV0d1LFusij64FsK--LtGfAMUu2vF |
| CitedBy_id | crossref_primary_10_3389_fpubh_2021_616456 crossref_primary_10_1007_s00103_021_03316_x crossref_primary_10_3389_fonc_2022_1049531 crossref_primary_10_1136_bmj_l4508 crossref_primary_10_31083_j_ceog5004082 crossref_primary_10_1002_14651858_CD013430_pub2 crossref_primary_10_1038_s41598_021_83727_7 crossref_primary_10_1016_j_vaccine_2021_02_039 crossref_primary_10_1093_jnci_djac189 crossref_primary_10_1016_j_vaccine_2020_06_057 crossref_primary_10_1038_s41598_021_99425_3 crossref_primary_10_1002_ijc_70119 crossref_primary_10_1007_s11864_025_01301_z crossref_primary_10_23950_jcmk_16590 crossref_primary_10_1007_s12326_021_00453_7 crossref_primary_10_1007_s13187_021_01995_3 crossref_primary_10_17645_mac_v8i2_2858 crossref_primary_10_18597_rcog_4310 crossref_primary_10_1155_2022_8052212 crossref_primary_10_1007_s00112_023_01857_w crossref_primary_10_1136_bmjopen_2019_035796 crossref_primary_10_1186_s12889_025_23496_4 crossref_primary_10_1080_14760584_2018_1548282 crossref_primary_10_3389_fonc_2022_856944 crossref_primary_10_1002_jmv_26968 crossref_primary_10_1016_j_vaccine_2020_09_015 crossref_primary_10_1002_cncy_70034 crossref_primary_10_58708_2074_2088_2025_1_33__38_46 crossref_primary_10_1007_s12672_022_00494_1 crossref_primary_10_1136_dtb_2020_000048 crossref_primary_10_30699_jogcr_7_5_405 crossref_primary_10_1071_SH22185 crossref_primary_10_15446_revfacmed_v68n1_73475 crossref_primary_10_31083_FBL36329 crossref_primary_10_1002_14651858_CD016121 crossref_primary_10_1186_s13643_020_01299_5 crossref_primary_10_1177_10598405231206109 crossref_primary_10_1016_j_vaccine_2019_12_019 crossref_primary_10_1016_j_ctrv_2022_102467 crossref_primary_10_1186_s13643_019_0983_y crossref_primary_10_2174_1381612826666200212115840 crossref_primary_10_1007_s00120_018_0795_z crossref_primary_10_1136_sextrans_2020_054855 crossref_primary_10_1038_s41598_022_12557_y crossref_primary_10_1016_j_ejogrb_2025_113994 crossref_primary_10_1016_j_vaccine_2021_08_085 crossref_primary_10_3389_fimmu_2023_1303893 crossref_primary_10_1093_heapro_daad153 crossref_primary_10_1111_jog_16330 crossref_primary_10_17116_repro202430051108 crossref_primary_10_1186_s13027_021_00399_8 crossref_primary_10_1080_21645515_2023_2180250 crossref_primary_10_1016_j_vaccine_2020_02_022 crossref_primary_10_3389_fpubh_2024_1453704 crossref_primary_10_1111_phn_13315 crossref_primary_10_1007_s12312_022_01063_x crossref_primary_10_1016_j_vaccine_2022_11_007 crossref_primary_10_1136_bmjopen_2023_074097 crossref_primary_10_1080_21645515_2025_2497608 crossref_primary_10_1515_med_2024_1101 crossref_primary_10_3201_eid2701_191364 crossref_primary_10_1016_j_vaccine_2021_02_040 crossref_primary_10_5604_01_3001_0015_2832 crossref_primary_10_1055_s_0042_1751331 crossref_primary_10_1007_s00053_021_00530_8 crossref_primary_10_1542_gr_45_1_11 crossref_primary_10_3390_vaccines10020178 crossref_primary_10_1016_j_vaccine_2020_02_075 crossref_primary_10_1186_s12889_023_16305_3 crossref_primary_10_1007_s11845_023_03551_y crossref_primary_10_1016_j_critrevonc_2024_104519 crossref_primary_10_3389_fonc_2023_1205553 crossref_primary_10_1007_s10699_020_09668_y crossref_primary_10_1055_a_2089_0722 crossref_primary_10_1186_s12885_022_10214_1 crossref_primary_10_1186_s12875_025_02910_1 crossref_primary_10_1071_MA20046 crossref_primary_10_1136_bmjopen_2018_026924 crossref_primary_10_1038_s41598_023_33476_6 crossref_primary_10_4274_eamr_galenos_2021_62634 crossref_primary_10_1136_bmjebm_2018_111119 crossref_primary_10_1007_s11654_022_00372_w crossref_primary_10_3389_fpubh_2025_1545171 crossref_primary_10_3389_fnut_2025_1624047 crossref_primary_10_1038_s41415_025_8439_3 crossref_primary_10_1159_000542618 crossref_primary_10_1007_s40136_023_00443_8 crossref_primary_10_1016_j_vaccine_2021_10_082 crossref_primary_10_1186_s12879_023_08737_4 crossref_primary_10_1007_s00281_018_0691_z crossref_primary_10_1017_S0950268818003679 crossref_primary_10_9745_GHSP_D_24_00282 crossref_primary_10_1136_bmjebm_2018_111101 crossref_primary_10_1001_jamanetworkopen_2024_22513 crossref_primary_10_1038_s41598_022_19798_x crossref_primary_10_1007_s40290_019_00288_x crossref_primary_10_1136_bmjebm_2018_111108 crossref_primary_10_3390_vaccines6030058 crossref_primary_10_3389_fonc_2020_00548 crossref_primary_10_7759_cureus_37512 crossref_primary_10_1111_odi_14559 crossref_primary_10_4102_sajid_v38i1_492 crossref_primary_10_1007_s10389_023_01918_0 crossref_primary_10_1136_bmjebm_2018_111012 crossref_primary_10_1007_s00105_020_04739_4 crossref_primary_10_1136_bmjopen_2021_057943 crossref_primary_10_1186_s12905_022_01930_8 crossref_primary_10_1001_jamanetworkopen_2024_11938 crossref_primary_10_1055_a_1378_7098 crossref_primary_10_1136_bmjopen_2023_072556 crossref_primary_10_1038_s41598_024_81726_y crossref_primary_10_1177_10436596211066809 crossref_primary_10_1136_bmjebm_2020_111470 crossref_primary_10_3389_fonc_2025_1592050 crossref_primary_10_1186_s13027_025_00682_y crossref_primary_10_1136_bmjebm_2018_111122 crossref_primary_10_1136_bmj_2022_070115 crossref_primary_10_1136_bmjebm_2018_111124 crossref_primary_10_3390_vaccines10122113 crossref_primary_10_1080_14760584_2023_2287135 crossref_primary_10_1134_S0003683821030121 crossref_primary_10_1136_practneurol_2020_002527 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/14651858.CD009069.pub3 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1469-493X |
| ExternalDocumentID | 29740819 |
| Genre | Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH 7X8 |
| ID | FETCH-LOGICAL-c5393-486de280059b9ab9d360f977333a62f8c2c94460d15caeae9b2e1630aa5efe382 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 423 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000433887900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1469-493X |
| IngestDate | Sun Nov 09 12:13:50 EST 2025 Tue Jun 24 01:32:05 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5393-486de280059b9ab9d360f977333a62f8c2c94460d15caeae9b2e1630aa5efe382 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| OpenAccessLink | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009069.pub3/pdf/full |
| PMID | 29740819 |
| PQID | 2036789035 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2036789035 pubmed_primary_29740819 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-09 |
| PublicationDateYYYYMMDD | 2018-05-09 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Cochrane database of systematic reviews |
| PublicationTitleAlternate | Cochrane Database Syst Rev |
| PublicationYear | 2018 |
| References | 29957861 - Cochrane Database Syst Rev. 2018 Jun 29;6:ED000126. doi: 10.1002/14651858.ED000126. 30277555 - Lakartidningen. 2018 Sep 28;115:FDC7. 29946934 - Urologe A. 2018 Jul;57(7):850-851. doi: 10.1007/s00120-018-0712-5. 25267916 - Cochrane Database Syst Rev. 2011;2011(4):CD009069. doi: 10.1002/14651858.CD009069. 30617051 - BMJ Evid Based Med. 2020 Apr;25(2):44-45. doi: 10.1136/bmjebm-2018-111122. |
| References_xml | – reference: 29957861 - Cochrane Database Syst Rev. 2018 Jun 29;6:ED000126. doi: 10.1002/14651858.ED000126. – reference: 25267916 - Cochrane Database Syst Rev. 2011;2011(4):CD009069. doi: 10.1002/14651858.CD009069. – reference: 29946934 - Urologe A. 2018 Jul;57(7):850-851. doi: 10.1007/s00120-018-0712-5. – reference: 30617051 - BMJ Evid Based Med. 2020 Apr;25(2):44-45. doi: 10.1136/bmjebm-2018-111122. – reference: 30277555 - Lakartidningen. 2018 Sep 28;115:FDC7. |
| SSID | ssj0039118 |
| Score | 2.6744843 |
| SecondaryResourceType | review_article |
| Snippet | Persistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | CD009069 |
| SubjectTerms | Adolescent Adult Female Human papillomavirus 16 Human papillomavirus 18 Humans Middle Aged Papillomavirus Infections - complications Papillomavirus Infections - mortality Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage Papillomavirus Vaccines - adverse effects Precancerous Conditions - mortality Precancerous Conditions - prevention & control Precancerous Conditions - virology Pregnancy Pregnancy Outcome Randomized Controlled Trials as Topic Uterine Cervical Dysplasia - mortality Uterine Cervical Dysplasia - prevention & control Uterine Cervical Dysplasia - virology Uterine Cervical Neoplasms - mortality Uterine Cervical Neoplasms - prevention & control Uterine Cervical Neoplasms - virology Vaccination Young Adult |
| Title | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29740819 https://www.proquest.com/docview/2036789035 |
| Volume | 5 |
| WOSCitedRecordID | wos000433887900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NT4MwFG_UGePF74_5lZp4xUELXXsyZrp42bKDJtxIaYshmYCw7e_3tTA9mZh4IYSGAK-_Pn6vr68_hO5sdSdhMvWEkD4EKDyEszDzIq4CmlHBuGnFJobTKY9jMesm3JpuWeXaJzpHrUtl58gHNmFmizZp9FB9elY1ymZXOwmNTdSjQGUsqofxdxaBwkDmbXWRVVKj8bpC2CeDwGqA84jfj56AZfhM2M-nv9NM97sZ7__3RQ_QXkc08WOLjEO0YYojtDPpUunHyMzqEkw8d0VSeCUVXHa9hOW7zIE0YiffhytZ5fN5-SFXeb1sTIMXJa7afZ-wco4GnqIsdmosC43zRWPb1RKYfN2coLfx8-voxes0FzwVUUG9kDNtCLc1qamQqdCU-RlwREqpZCTjiigBEaSvg0hJI41IiQFK50sZmcxQTk7RVlEW5hxhJpjm2mgI8LJQQFuQDk0QpgTCPkCA6aPbtQETwLRNVMjClMsm-TFhH521vZBU7eYbCYEAyNKYiz_cfYl2gd9wtz5RXKFeBiPaXKNttVrkTX3jwALH6WzyBfRpyb4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prophylactic+vaccination+against+human+papillomaviruses+to+prevent+cervical+cancer+and+its+precursors&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=Arbyn%2C+Marc&rft.au=Xu%2C+Lan&rft.au=Simoens%2C+Cindy&rft.au=Martin-Hirsch%2C+Pierre+Pl&rft.date=2018-05-09&rft.eissn=1469-493X&rft.volume=5&rft.spage=CD009069&rft_id=info:doi/10.1002%2F14651858.CD009069.pub3&rft_id=info%3Apmid%2F29740819&rft_id=info%3Apmid%2F29740819&rft.externalDocID=29740819 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1469-493X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1469-493X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1469-493X&client=summon |